Searchable abstracts of presentations at key conferences in endocrinology

ea0022p313 | Diabetes | ECE2010

Fifty-two-week treatment with diet and exercise plus transdermal testosterone improves biomarkers of non-alcoholic fatty liver disease and cardiovascular risk in hypogonadal men with the metabolic syndrome

Saad Farid , Heufelder Armin , Bunck Mathijs , Gooren Louis

Objectives: Men with the metabolic syndrome (MetS) and type 2 diabetes (T2D) often have low testosterone levels. Elevating low testosterone levels may improve features of the MetS and glycemic control. In this analysis, we assessed effects of normalization of circulating testosterone on biomarkers of non-alcoholic fatty liver disease (NAFLD), and cardiovascular risk.Design and methods: In a single-blind, 52-week clinical trial, 32 hypogonadal men with th...

ea0003oc33 | Hormone Action | BES2002

The role of the PPAR gamma in thyroid eye disease: Possible contra-indication for thiazolidenedione therapy

Starkey K , Heufelder A , Evans L , Davies J , Baker G , Ludgate M

A male patient treated with a thiazolidenedione (TZD) PPAR gamma agonist for Type 2 diabetes had a dramatic worsening of his thyroid eye disease (TED), which had been stable and inactive for more then two years. Expansion of the orbital fat seemed to be the underlying cause and we have investigated the effects of a PPAR gamma agonist (and subsequently an antagonist) on the adipogenesis of preadipocytes from 10 different patients, representing several fat depots, including TED ...